|
Published by: Kalorama Information
Published: Jul. 1, 1995 - 172 Pages Now 50% off the original sale price of $3,250.
Table of Contents
Chapter One: Executive Summary
- Introduction to Monoclonal Antibodies
- Monoclonal Antibody Development
- Chimeric Monoclonals
- Humanized and Human Monoclonals
- Bispecific Monoclonals
- Mechanism of Action
- Diagnostic
- Therapeutic
- Monoclonal Antibody Product Classifications
- Diagnostics
- Conventional Diagnostics
- Infectious Disease
- Evolving Diagnostics
- Cancer
- Cardiovascular
- Evolving Therapeutics
- Cancer
- Cardiovascular Disease
- Infectious Disease
- Inflammation
- Rheumatoid Arthritis
- Transplant
- Marketing and Use of Monoclonals
- Hospitals and Clinics
- Physicians' Offices
- Issues and Trends
- Drug Development Strategies
- Biotech/Pharmaceutical Alliances
- The Market
- Historic Growth
- Forecast
Chapter Two: Introduction to Monoclonal Antibodies
- Monoclonal Antibody Definition and Development
- Monoclonal Derivation
- Murine Model Disadvantages
- Chimeric Monoclonals
- Humanized
- Human
- Bispecific
- Immunotoxins
-
- Mechanism of Action
- Diagnostic
- Therapeutic
- Monoclonal Antibody Products
- Diagnostics
- Therapeutics
- The Monoclonal Antibody Industry
- History
- Early Development
- Future Trends
- Manufacturers
- Biotechnology Companies
- Pharmaceutical Companies
- Alliances
- Distributors
- Physicians' Offices
- Hospitals and Clinics
Chapter Three: Description of Diagnostic Monoclonal Antibodies
- Introduction
- Conventional MAb Diagnostics
- Infectious Disease
- Chlamydia
- Disease Description
- Product Evolution
- Product Types
- Cytomegalovirus
- Disease Description
- Product Evolution
- Product Types
- Herpes
- Disease Description
- Product Evolution
- Product Types
- Human Immunodeficiency Virus
- Disease Description
- Product Evolution
- Product Types
- Syphilis
- Disease Description
- Product Evolution
- Product Types
- Evolving MAb Diagnostics
- Cancer
- Breast
- Disease Description
- Product Evolution
- Product Types
- Colorectal
- Disease Description
- Product Evolution
- Product Types
- Lung
- Disease Description
- Product Evolution
- Product Types
- Ovary
- Disease Description
- Product Evolution
- Product Types
- Cardiovascular
- Disease Description
- Product Evolution
- Product Types
- Other Evolving Diagnostics
Chapter Four: Description of Therapeutic Monoclonal Antibodies
- Cancer
- Breast
- Disease Description
- Product Evolution
- Product Types
- Colorectal
- Disease Description
- Product Evolution
- Product Types
- Leukemia
- Disease Description
- Product Evolution
- Product Types
- Lymphoma
- Disease Description
- Product Evolution
- Product Types
-
- Ovary
- Disease Description
- Product Evolution
- Product Types
- Small Cell Lung Cancer
- Disease Description
- Product Evolution
- Product Types
- Cardiovascular Disease
- Disease Description
- Product Evolution
- Product Types
- Infectious Disease
- Cytomegalovirus
- Disease Description
- Product Types
- Human Immunodeficiency Virus
- Disease Description
- Product Evolution
- Product Types
- Sepsis
- Disease Description
- Product Types
- Inflammation
- Disease Description
- Product Types
- Rheumatoid Arthritis
- Disease Description
- Product Evolution
- Product Types
- Transplant
- Bone Marrow
- Disease Description
- Product Types
- Heart
- Disease Description
- Product Types
- Kidney
- Disease Description
- Product Evolution
- Product Types
- Other Kidney Transplant MAb Products in Development
- Other MAb Therapy Approaches
Chapter Five: Issues and Trends
- Research and Development Trends
- Products
- Regulatory Issues
- CLIA Laboratory Regulations
- FDA Drug Evaluation Process
- Orphan Drug
- Drugs for Life-Threatening Illness
- Treatment INDs
- Parallel Tracking
- Patent Issues
- Business Development Strategies
- Strategic Alliances
- Co-Marketing and Distribution
Chapter Six: The Market
- Sales and Forecast
- Historic Growth
- Forecast
- Notes on the Data
- Diagnostics
- Cancer
- Cardiovascular
- Infectious Disease
- Market Trends
- Therapeutics
- Cancer
- Cardiovascular
- Infectious Disease
- Inflammation
- Rheumatoid Arthritis
- Transplant
- Market Trends
- Market Competition
Chapter Seven: Company Profiles
- Biomira Inc.
- History and Lines of Business
- Research and Development
- Corporate Strategies
- Biomira Research, Inc.
- ADI Diagnostics, Inc.
- Cell Genesys
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- CellPro
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Centocor
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Eli Lilly
- Wellcome
- Tanabe Seiyaku Co., Ltd.
- Chiron
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategy
- Coulter Electronics Inc.
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Cytogen
- History and Lines of Business
- Financial Information
- ProstaScint Research and Development
- Corporate Strategies
- GenPharm International
- History and Lines of Business
- Financial Information
- Research and Development
- Eli Lilly & Company
- Eisai Co., Ltd.
- Corporate Strategies
- IDEC Pharmaceuticals
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- ImmunoGen
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Immunomedics
- History and Lines of Business
- Financial Information
- Research and Development
- Diagnostics
- Therapeutics
- Corporate Strategies
- Ixsys
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Medarex
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Neoprobe
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- NeoRx
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- Ortho Biotech
- History and Lines of Business
- Financial Information: Johnson & Johnson
- Research and Development
- Corporate Strategies
- Pfizer
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
-
- Protein Design Laboratories
- History and Lines of Business
- Financial Information
- Research and Development
- Corporate Strategies
- The Wellcome Foundation, Ltd.
- History and Lines of Business
- Financial Information: The Wellcome Foundation, Ltd.
- Research and Development
- Centocor
- Sterling Winthrop
- Corporate Strategies
Appendix: Company Names and Addresses
List of Exhibits
Chapter One: Executive Summary
Table 1-1: The U.S. Market for Monoclonal Antibody Products, 1989-1999
Chapter Two: Introduction to Monoclonal Antibodies
Table 2-1: Monoclonal Antibody Products, by Category, Company, Product Name,
and U.S. Development Status, 1995
Table 2-2: Selected Pharmaceutical and Biotechnology Alliances
Chapter Three: Description of Diagnostic Monoclonal Antibodies
Table 3-1: Conventional MAb Diagnostics, by Disease and Company
Table 3-2: Evolving MAb Diagnostics, by Disease and Company
Chapter Four: Description of Therapeutic Monoclonal Antibodies
Table 4-1: MAb Therapeutics, by Company and Disease
Chapter Six: The Market
Table 6-1: The U.S. Market for Diagnostic and Therapeutic Monoclonal Antibody
Products, 1989-1999
Table 6-2: The U.S. Market for Diagnostic Cancer Monoclonal Antibody
Products, 1989-1999
Table 6-3: The U.S. Market for Diagnostic Cardiovascular Monoclonal Antibody
Products, 1989-1999
Table 6-4: The U.S. Market for Diagnostic Infectious Disease Monoclonal Antibody
Products, 1989-1999
Table 6-5: The U.S. Market for Therapeutic Cancer Monoclonal Antibody
Products, 1989-1999
Table 6-6: The U.S. Market for Cardiovascular Therapeutic Monoclonal Antibody
Products, 1989-1999
Table 6-7: The U.S. Market for Therapeutic Infectious Disease Monoclonal
Antibody Products, 1989-1999
Table 6-8: The U.S. Market for Therapeutic Inflammation Monoclonal
Antibody Products, 1989-1999
Table 6-9: The U.S. Market for Therapeutic Rheumatoid Arthritis Monoclonal
Antibody Products, 1989-1999
Table 6-10: The U.S. Market for Therapeutic Transplant Monoclonal
Antibody Products, 1989-1999
Table 6-11: Monoclonal Antibody Products, by Company, Category, Disease,
Product Name, and U.S. Development Status, 1995
AbstractOnce dubbed the magic bullet for treating cancer and other complex diseases, monoclonal antibodies are entering a period of tremendous growth potential. This comprehensive new report by Kalorama Information discusses the latest advances and the critical role MABs will play in the future. Explains which new MABs will be instrumental in treating organ transplants, cancer, sepsis, infectious diseases, and sexually transmitted diseases. Covers new developments in diagnostic MABs that will address several major diseases, MABs already on the market, and new drugs in development or seeking approval with the U.S. Food and Drug Administration (FDA). Analyzes the history of the MAB industry, its major research and market trends, and forecasts of market size through 1999.
Get Full Details About This Report >>
|
